SEC Form 4 · accession 0001144204-17-053032
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F Cola
Officer — President and CEO · Director
Period of report
Oct 17, 2017
Accepted (ET)
Oct 18, 2017 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 17, 2017 | P | 119,047 | $1.26 | A | 218,483 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy) | $2.84 | Oct 17, 2017 | P | 21,181 | A | Oct 17, 2017 | Oct 17, 2022 | Common Stock | 21,181 | 21,181 | D |